1-2 of 2
Quincy Chau
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Everolimus for Relapsed/Refractory Classical Hodgkin Lymphoma: Multicenter, Open-Label, Single-Arm, Phase 2 Study.

Patrick B. Johnston, MD, PhD, Lauren Pinter-Brown, MD, Jaqueline Rogerio, MD, Ghulam Warsi, PhD, Quincy Chau, MD, MSc, Radhakrishnan Ramchandren, MD
Journal: Blood
Blood (2012) 120 (21): 2740.
https://doi.org/10.1182/blood.V120.21.2740.2740
Published: 2012
Journal Articles

PILLAR-1: Preliminary Results of a Phase II Study of mTOR Inhibitor Everolimus In Patients with Mantle Cell Lymphoma (MCL) Who Are Refractory or Intolerant to Bortezomib

Owen A. O'Connor, MD, PhD, Leslie Popplewell, M.D., Jane N. Winter, M.D., RuiRong Yuan, MD, PhD, Anna Robeva, MS, Helene Cauwel, Quincy Chau, Michael Wang, MD
Journal: Blood
Blood (2010) 116 (21): 3963.
https://doi.org/10.1182/blood.V116.21.3963.3963
Published: 2010